September 18, 2025

Comprehensive Risks and Strategic Resilience in the U.S. Pharmaceutical Supply Chain

View Full Paper

Ask AI

Bookmark

Over 80% of active pharmaceutical ingredients are produced outside the U.S., indicating a significant dependency risk.
The COVID-19 pandemic exposed vulnerabilities, resulting in nationwide shortages of essential medications.
Strategies for enhancing reliability include regulatory reform initiatives and domestic manufacturing expansion.
Establishing mandatory supply chain mapping requirements could improve transparency and resilience during disruptions.

Discussion

No takes yet. Share an insight, caveat, or question.

This research identifies vulnerabilities in the pharmaceutical supply chain, proposing strategies for resilience and regulatory frameworks.

Gupta et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

This research identifies vulnerabilities in the pharmaceutical supply chain, proposing strategies for resilience and regulatory frameworks.